Back to search results
NCT05332054

Long-Term Follow-up Study

Enrolling by Invitation
Not specifiedAges 18+Observational
Caribou Biosciences, Inc.
~150 participants
Updated 2026-03-12 on ClinicalTrials.gov
What's tested:Caribou-sponsored investigational therapy

At a glance

Recruiting sites
0 of 31 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of targeted NSAEs
Measured over 15 Years
+12 more outcomes measured

Conditions

Lymphoma, Non-Hodgkin
Relapsed Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Lymphoma
B Cell Lymphoma
B-Cell Non-Hodgkin's Lymphoma
Hematologic Malignancy
Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Acute Myeloid Leukemia

Explore related trials

Acute Myeloid LeukemiaB-Cell Non-Hodgkin LymphomaMalignant neoplasm of lymphoid, hematopoietic and/or related tissueMultiple Myeloma

NCT05332054

Where you'd take part

This study runs at 31 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • AdventHealth Medical Group Blood & Marrow Transplant at Orlando

    Orlando, Floridano site contact published

  • Atlantic Health System Cancer Care

    Morristown, New Jerseyno site contact published

  • Augusta University/Georgia Cancer Center

    Augusta, Georgiano site contact published

  • Banner MD Anderson Cancer Center

    Gilbert, Arizonano site contact published

  • Baylor Research Institute

    Dallas, Texasno site contact published

  • Blood & Marrow Transplant Group of Georgia

    Atlanta, Georgiano site contact published

  • Cleveland Clinic

    Cleveland, Ohiono site contact published

  • Colorado Blood Cancer Institute

    Denver, Coloradono site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent (by patient or legal representative) obtained prior to study-specific activities/enrollment
Completed a Caribou-sponsored study or was administered Caribou IP under a special access program or as part of an IIT
Use of an effective method of birth control by women of childbearing potential and their partners and men with partners of childbearing potential (partners must also use an effective birth control method) through 12 months post IP infusion.

Exclusion

None

What this trial measures

  • Incidence of targeted NSAEs15 Years

    Incidence of targeted NSAEs

  • Frequency of targeted NSAEs15 Years

    Frequency of targeted NSAEs

  • Duration of targeted NSAEs15 Years

    Duration of targeted NSAEs

  • Outcome of targeted NSAEs15 Years

    Outcome of targeted NSAEs

  • Incidence of AESIs15 Years

    Incidence of AESIs

  • Frequency of AESIs15 Years

    Frequency of AESIs

  • Duration of AESIs15 Years

    Duration of AESIs

  • Outcome of AESIs15 Years

    Outcome of AESIs

  • Incidence of targeted SAEs15 Years

    Incidence of targeted SAEs

  • Frequency of targeted SAEs15 Years

    Frequency of targeted SAEs

  • Duration of targeted SAEs15 Years

    Duration of targeted SAEs

  • Outcome of targeted SAEs15 Years

    Outcome of targeted SAEs

  • Incidence of AEs related to IP leading to death15 Years

    Incidence of AEs related to IP leading to death